-
Science Corporation Acquires Pixium’s PRIMA Retinal Implant, Extending and Diversifying Its Commitment to Vision Restoration Through Brain-Computer Interface Technology
25 Apr 2024 11:21 GMT
… promise. The early clinical trial results we’ve seen are … severe vision loss due to retinal degeneration caused by the dry … till now there is no treatment available.
The Science Eye, … are no treatment options. Its first product in development, the Science …
-
NPHP5 Retinal Degeneration Treatment Market Overall Study Report 2024-2031 | jCyte, Inc., Biogen, Novartis AG
10 Apr 2024 07:40 GMT
… Pharmacies, Online Pharmacies
Geographically, the detailed analysis of consumption, revenue, Global NPHP5 Retinal Degeneration Treatment … Global NPHP5 Retinal Degeneration Treatment market, including research and development initiatives, collaborations …
-
Disease modeling and pharmacological rescue of autosomal dominant Retinitis Pigmentosa associated with RHO copy number variation
12 Apr 2024 04:56 GMT
… cells), and the developmental timeline of the retina … 1), with outer retinal atrophy due to the loss … causative variants of inherited retinal degeneration candidate genes were identified … biological replicates.
PR3 treatment on Retinal Organoids
Patient …
-
Kiora Pharmaceuticals Receives Grant from Choroideremia Research Foundation to Fund Novel Clinical Trial Endpoints for Inherited Retinal Diseases; Approval Granted to Initiate Clinical Validation Study
11 Apr 2024 21:39 GMT
… 11, 2024) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) … trial, a feasibility study assessing safety and efficacy of its investigational drug … meeting with the US FDA, Kiora and Ora … related retinal degeneration. KIO-104 is being developed for the treatment of …
-
Metabolome rejuvenation can slow retinal degeneration
22 Mar 2024 13:41 GMT
World Eyes
But there's a huge obstacle: RP can be caused by mutations in over 80 different genes. To treat most RP patients with gene therapy, researchers would have to create a therapy for each gene—a nearly impractical task using current gene …
-
Kiora Pharmaceuticals to Present at Upcoming Investor Conferences
05 Apr 2024 11:27 GMT
… April 5, 2024) - Kiora Pharmaceuticals (NASDAQ: KPRX) invites investors to … age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior …
-
Kiora Pharmaceuticals to Present Additional Data from Its ABACUS-1 Trial in Retinitis Pigmentosa at the ARVO 2024 Annual Meeting
28 Mar 2024 15:51 GMT
… 28, 2024) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), … multicenter, controlled clinical trial for retinitis pigmentosa. … treatment for RP could meet this need. This drug is being developed … retinal degeneration. KIO-104 is being developed for the treatment …
-
Opus Genetics Advances with Novel LCA5 Gene Therapy in Phase 1/2 Clinical Trial
27 Mar 2024 13:34 GMT
… innovative clinical trial, focusing on a new treatment for patients … form of early-onset retinal degeneration, affecting roughly one in … with no currently approved treatments for those experiencing vision loss … has been challenging to treat due to the genetic …
-
Gene therapy improves vision in patients with retinitis pigmentosa in phase 2b trial
27 Mar 2024 17:35 GMT
… license application to the FDA for MCO-010 later … trial.
“MCO-010 would, for the first time, provide ophthalmologists a treatment … 100-plus mutations caused the retinal degeneration,” Samuel Barone, MD, chief … license application to the FDA for MCO-010 before …
-
Opus Genetics Announces Completion of Dosing in First Cohort of Phase 1/2 Trial of Gene Therapy OPGx-LCA5 in Patients with Rare Inherited Retinal Disease LCA5
26 Mar 2024 12:00 GMT
… clinical-stage gene therapy company developing treatments for inherited retinal diseases, today … .” For more information on the trial, visit clinicaltrials.gov (NCT05616793). … in nine patients with inherited retinal degeneration due to biallelic mutations in …